Activist investor Bluebell Capital has built a stake in Bayer and is pushing the company to break up crop science unit from its pharmaceutical business, according to Bloomberg’s Crystal Tse, Swetha Gopinath and Aaron Kirchfeld, citing sources. Bluebell is also seeking an overhaul of the German company’s corporate governance, according to the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BAYRY: